Neuraxial pain relief for intractable cancer pain

Current Pain and Headache Reports

Volumn 11, Issue 4, 2007, Pages 283-289

  Sloan, Paul A ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BACLOFEN; BUPIVACAINE; CHOLINESTERASE INHIBITOR; CLONIDINE; DROPERIDOL; FENTANYL; HEPARIN; HYDROMORPHONE; KETAMINE; LIDOCAINE; LOCAL ANESTHETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; METHADONE; MIDAZOLAM; MORPHINE; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA CONOTOXIN MVIIA; OPIATE DERIVATIVE; PETHIDINE; ROPIVACAINE; SOMATOSTATIN DERIVATIVE; SUFENTANIL; TETRACAINE;

ABSENCE OF SIDE EFFECTS; ADRENAL CORTEX INSUFFICIENCY; ANALGESIC ACTIVITY; BLOOD CLOTTING DISORDER; BRADYCARDIA; CANCER PAIN; CANCER PATIENT; CARDIOTOXICITY; CATHETER COMPLICATION; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INFUSION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSPHORIA; EPIDURAL CATHETER; HEALTH CARE COST; HUMAN; HYPERALGESIA; HYPOGONADISM; HYPOTENSION; INFUSION PUMP; INTRACTABLE PAIN; LOW DRUG DOSE; MICTURITION DISORDER; MONOTHERAPY; MOTOR DYSFUNCTION; MOTOR NERVE BLOCK; MYOCLONUS; NAUSEA; NAUSEA AND VOMITING; NERVE BLOCK; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NEUROPATHIC PAIN; NEUROTOXICITY; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PATIENT CARE; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PROGNOSIS; PRURITUS; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; SENSORY DYSFUNCTION; SIDE EFFECT; SPINAL ANESTHESIA; SYMPATHETIC BLOCKING; TACHYPHYLAXIS; UNSPECIFIED SIDE EFFECT; URINE RETENTION;

ANALGESIA, EPIDURAL; ANALGESICS, OPIOID; ANESTHETICS, LOCAL; HUMANS; INFUSION PUMPS; INFUSIONS, PARENTERAL; NEOPLASMS; PAIN, INTRACTABLE;

EID: 34547564899     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-007-0205-5     Document Type: Review

References (45)

1. Sloan PA, Slatkin NE, Ahdieh H: Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Support Care Cancer 2005, 13:57-65.
2. Melzack R, Ofiesh JG, Mount BM: The Brompton mixture: effects on pain in cancer patients. Can Med Assoc J 1976, 115:125-129.
3. Schug SA, Zech D, Dorr U: Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage 1990, 5:27-32.
4. Sloan PA, Melzack R: Long-term patterns of morphine dosage and pain intensity among cancer patients. Hosp J 1999, 14:35-47.
5. Sloan PA: The evolving role of interventional pain management in oncology. J Support Oncol 2004, 2:1-11.
6. Mercandante S, Portenoy RK: Opioid poorly responsive cancer pain, part 3: clinical strategies to improve opioid responsiveness. J Pain Symptom Manage 2001, 21:338-354.
7. Meyerson BA: Neurosurgical approaches to pain treatment. Acta Anaesthesiol Scand 2001, 45:1108-1113.
8. Kedlaya D, Reynolds L, Waldman S: Epidural and intrathecal analgesia for cancer pain. Best Prac Res Clin Anaesth 2002, 16:651-665.
9. Mercadante S: Problems of long-term spinal opioid treatment in advanced cancer patients. Pain 1999, 79:1-13.
10. Melzack R, Wall PD: Pain mechanisms: a new theory. Science 1965, 150:171-179.
11. Pert CB, Snyder SH: Opiate receptor: demonstration in nervous tissue. Science 1973, 179:1011-1014.
12. Wang JK, Nauss LA, Thomas JE: Pain relief by intrathecally applied morphine in man. Anesthesiology 1979, 50:149-151.
13. Mercadante S: Intrathecal morphine and bupivacaine in advanced cancer pain patients implanted at home. J Pain Symptom Manage 1994, 9:201-207.
14. Stearns L, Boortz-Marx R, Du Pen S, et al.: Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices. J Support Oncol 2005, 3:399-408.
15. Krames ES: Practical issues when using neuraxial infusion. Oncology 1999, 13:S37-S44.
16. Mercadante S: Neuraxial techniques for cancer pain: an opinion about unresolved therapeutic dilemmas. Reg Anesth Pain Med 1999, 24:74-83.
17. Paice JA, Winkelmuller W, Burchief K, et al.: Clinical realities and economic considerations: efficacy of intrathecal pain therapy. J Pain Symptom Manage 1997, 14:S14-S26.
18. Follett KA, Hitchon PW, Piper J, et al.: Response of intractable pain to continuous intrathecal morphine: a retrospective study. Pain 1992, 49:21-25.
19. Sallerin-Caute B, Lazorthes Y, Deguine O, et al.: Does intrathecal morphine in the treatment of cancer pain induce the development of tolerance? Neurosurgery 1998, 42:44-49.
20. Samuelsson H, Malber F, Eriksson M, Hedner T: Outcomes of epidural morphine treatment in cancer pain: nine years of clinical experience. J Pain Symptom Manage 1995, 10:105-112.
21. Nitescu P, Dahm P, Appelgren L, Curelaru I: Continuous infusion of opioid and bupivacaine by externalized intrathecal catheters in long-term treatment of refractory nonmalignant pain. Clin J Pain 1998, 14:17-28.
22. Du Pen SL, Kharash ED, Williams A, et al.: Chronic epidural bupivacaine-opioid infusion in intractable cancer pain. Pain 1992, 49:293-300.
23. van Dongen RT, Crul BJ, van Egmond J: Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain 1999, 15:166-172.
24. Mercadante S, Villari P, Ferrera P, Arcuri E: Local anesthetic switching for intrathecal tachyphylaxis in cancer patients with pain. A nesth Analg 2003, 97:187-189.
25. Eisenach JC, Du Pen S, Dubois M, et al.: Epidural clonidine analgesia for intractable cancer pain. Pain 1995, 61:391-399.
26. Yang CY, Wong CS, Chang JY, Ho ST: Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can J Anesth 1996, 43:379-383.
27. Walker SM, Goudas LC, Cousins MJ, Carr DB: Combination spinal analgesic chemotherapy: a systematic review. Anesth Analg 2002, 95:674-715.
28. Vranken JH, Troost D, de Hann P, et al.: Severe toxic damage to the rabbit spinal cord after intrathecal administration of preservative-free S(+)-ketamine. Anesthesiology 2006, 105:813-818.
29. Doggrell SA: Intrathecal ziconotide for refractory pain. Expert Opin Investig Drugs 2004, 13:875-877.
30. Sloan PA, Hamann SR: Ultra low-dose opioid antagonists to enhance opioid analgesia. J Opioid Manage 2006, 2:295-304.
31. Smith TJ, Coyne PJ: How to use implantable intrathecal drug delivery systems for refractory cancer pain. J Support Oncol 2003, 1:73-76.
32. Brogan SE: Intrathecal therapy for the management of cancer pain. Curr Pain Headache Rep 2006, 10:254-259.
33. Bedder MD, Burchiel K, Larson A: Cost analysis of two implantable narcotic delivery systems. J Pain Symptom Manage 1991, 6:368-373.
34. Han KR, Kim C, Park SK, Kim JS: Distance to the adult cervical epidural space. Reg Anesth Pain Med 2003, 28:95-97.
35. Bennett G, Burchiel K, Buchser E, et al.: Clinical guidelines for intraspinal infusion: report of an expert panel. J Pain Symptom Manage 2000, 20:S37-S43.
36. Smith TJ, Staats PS, Deer T, et al.: Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002, 20:4040-4049.
37. Cerda-Olmedo G, De Andres J, Moliner S: Management of progressive pain in a patient with intramedullary chordoma of the spine. Clin J Pain 2002, 18:128-131.
38. Lazorthes Y, Sagen J, Sallerin B, et al.: Human chromaffin cell graft into the CSF for cancer pain management: a prospective phase II clinical study. Pain 2002, 87:19-32.
39. Nitescu P, Sjoberg M, Appelgren L, Curelaru I: Complications of intrathecal opioids and bupivacaine in the treatment of refractory cancer pain. Clin J Pain 1995, 11:45-62.
40. Basta M, Sloan PA: Epidural hematoma following epidural catheter placement in a patient with chronic renal failure. Can J Anesth 1999, 46:271-274.
41. Ubogu EE, Lindenberg JR. Werz MA: Transverse myelitis associated with Acinetobacter baumanii intrathecal pump catheter-related infection. Reg Anesth Pain Med 2003, 28:470-474.
42. van Dongen RT, van Ee R, Crul BJ: Neurological impairment during long-term intrathecal infusion of bupivacaine in cancer patients: a sign of spinal cord compression. Pain 1997, 69:205-209.
43. Allen JW, Horais KA, Tozier NA, et al.: Time course and role of morphine dose and concentration in intrathecal granuloma formation in dogs. Anesthesiology 2006, 105:581-589.
44. Hassenbusch S, Burchiel K, Coffey RJ, et al.: Management of intrathecal catheter-tip inflammatory masses: a consensus statement. Pain Med 2002, 3:313-323.
45. Coffey RJ, Burchiel K: Inflammatory mass lesions associated with intrathecal drug infusion catheters: report and observations on 41 patients. Neurosurgery 2002, 50:78-86.